A recently released report projects the world market for artificial intelligence (AI) and machine learning in medical imaging, including software for automated detection, quantification, decision support and diagnosis, will reach $2 billion by 2023. According to the report’s author, analyst Simon Harris, “The interest and enthusiasm for AI in the radiologist community has notably increased over the last 12 to 18 months and the discussion has moved on from AI as a threat to how AI will augment radiologists.”

Yet, Harris notes in his report that several barriers remain. The regulatory process remains challenging and more large-scale validation studies are needed to demonstrate the performance of deep learning algorithms in clinical settings. Additionally, with many start-up and specialist companies driving the application of machine learning to medical imaging, there is also the issue of integration challenges with established medical imaging software and systems.

Regardless of these barriers, Harris is optimistic in his view of the future. “Over the coming years, the combined R&D firepower of the expanding ecosystem will knock down the remaining barriers and radiologists will have a rapidly expanding array of AI-powered workflow and diagnostic tools at their disposal,” he says.

Breast cancer screening can lead to the detection of benign (noncancerous) findings, and reducing biopsies and surgeries of these benign findings is one clinical area where there has been much activity by industry and academia. Researchers at Massachusetts Institute of Technology’s (MIT) Computer Science and Artificial Intelligence Laboratory (CSAIL), Massachusetts General Hospital and Harvard Medical School collaborated to develop a machine learning model to predict if a high-risk breast lesion identified on biopsy will be upgraded to cancer at surgery, or whether the lesion could be safely surveilled. Tested on 335 high-risk lesions, the model correctly diagnosed 97% of the breast cancers as malignant and reduced benign lesion surgeries by more than 30% compared to current methods.

Breast cancer screening can lead to the detection of benign (noncancerous) findings, and reducing biopsies and surgeries of these benign findings is one clinical area where there has been much activity by industry and academia. Researchers at Massachusetts Institute of Technology’s (MIT) Computer Science and Artificial Intelligence Laboratory (CSAIL), Massachusetts General Hospital and Harvard Medical School collaborated to develop a machine learning model to predict if a high-risk breast lesion identified on biopsy will be upgraded to cancer at surgery, or whether the lesion could be safely surveilled. Tested on 335 high-risk lesions, the model correctly diagnosed 97% of the breast cancers as malignant and reduced benign lesion surgeries by more than 30% compared to current methods. Currently, only 30% of breast biopsies are positive for cancer.

“No existing imaging method can determine which high-risk lesions will be upgraded to cancer at surgery and which won’t be,” says Manisha Bahl, MD, MPH, Director, Breast Imaging Fellowship Program at Massachusetts General Hospital (MGH) and lead author of the study. “Management of high-risk lesions is controversial; most are non-cancerous but surgery is recommended because high-risk lesions have the potential to be upgraded to cancer at the time of surgery.”

Dr. Bahl says that Regina Barzilay, MIT’s Delta Electronics Professor of Electrical Engineering and Computer Science, was inspired to apply her expertise in AI in breast cancer after her own experience with breast cancer detection and treatment. She partnered with Constance Lehman, MD, professor of radiology and chief of breast imaging at MGH and Dr. Bahl to apply AI across various projects—from high-risk lesions to ductal carcinoma in situ (DCIS) and mammogram interpretation. While the high-risk lesion algorithm has yet to be implemented into clinical practice at MGH, Dr. Bahl says they are using an algorithm developed through the MIT-MGH collaboration that assesses breast density.

At RSNA 2017, researchers from Radboud University Medical Centre in Nijmegen, Netherlands, presented findings that compared the performance of experienced radiologists with Transpara (ScreenPoint Medical BV, Nijmegen, The Netherlands), a deep learning computer detection system, in detecting breast cancer on mammograms.

The study included 24 radiologists who retrospectively reviewed more than 1,400 2D digital mammography
To train the CNN, the researchers exposed the program to thousands of pathology images of known breast, lung and bladder cancers. Then, the researchers obtained more than 13,000 new pathology images of breast, lung and bladder cancer to test the algorithms. The network distinguished the type of cancer in the samples with 100% accuracy and could also determine lung cancer subtypes with 92% accuracy. Additionally, the program identified biomarkers for breast and bladder cancer with 91% and 99% accuracy, respectively.2

In the UK, a consortium of leading breast cancer experts, clinicians, academia and AI industry are partnering to explore whether AI can help to detect and diagnose breast cancer more efficiently. Led by Imperial College London, the consortium is based at the Cancer Research UK Imperial Centre—a partnership between the college, Imperial College Healthcare NHS Trust and Cancer Research UK—and will work with DeepMind Health and the AI health research team at Google.

Machine learning technology from DeepMind Health and the AI research team at Google will be applied to approximately 7,500 mammograms provided by the Cancer Research UK-funded OPTIMAM database at the Royal Surrey County Hospital NHS Foundation Trust. The team plans to evaluate the possibility of training the computer algorithm to analyze the images for signs of cancer and alert radiologists more accurately than is possible with current technology.

“Radiology has already benefitted so much from advances in technology and the implementation of AI will be another giant leap for our specialty,” says Alyssa Watanabe, MD, Clinical Associate Professor at the University of Southern California Keck School of Medicine and Chief Medical Officer at CureMetrix, Inc. “AI will be a tremendous boost for breast imaging. Mammography is truly the most difficult to read of all medical imaging studies.”

She adds, “Half of breast cancers can be seen retrospectively and tremendous resources are spent on false positive workups and biopsies. Improving accuracy and reducing costs will give more strength to the benefits of mass breast cancer screening.”

Dr. Watanabe has been involved in several clinical studies evaluating CureMetrix’s technology as part of a team of researchers at USC. At RSNA 2017, she presented results that showed approximately 50% of benign biopsies could be eliminated with the use of AI-based biopsy classifier software for mammography. At this year’s meeting, she’ll present results from a reader’s study that shows a statistically significant benefit from the use of AI in medical imaging.

According to Dr. Watanabe, the most desired improvement for imaging analysis software in mammography is the reduction in false positives per image (FPPI). In one study conducted by CureMetrix, 28% of false positive recalled cases could have been avoided. Another study reported a 69% reduction in false positive flags per image or FPPI compared to traditional CAD. A third study, a retrospective study of mammograms where breast cancers were initially missed using conventional CAD, cancer detection rates increased 27% on average yet false positive markings increased by less than 1%.

“Any method to improve the performance of mammography interpretation could tremendously affect patient care, radiologist workflow and system costs,” Dr. Watanabe says.

“Clever algorithms based on AI/machine learning make CAD more intelligent and effective, improving lesion detection and classification,” says Lawrence Tanenbaum, MD, FACS, Director of MRI, CT and Advanced Imaging, and Vice President and Medical Director, Eastern Operations, RadNet, Inc.
A quick look at several new and emerging technologies utilizing AI in breast imaging. Some products are works-in-progress and may not have received regulatory clearance in the U.S.

**Curemetrix**
Focused on developing next generation medical image analysis technology for breast health exams, Curemetrix’s cmAssist is an investigational CAD that has the potential to quickly detect key regions of interest on a mammogram, and accurately quantify and classify the anomalies as suspicious or verifiably benign. Through the use of AI and deep machine learning, cmAssist generates both markings like traditional CAD and a quantitative likelihood of malignancy for each region of interest on the breast, which is called the neuScore. The neuScore is a numerical ranking for each lesion on a scale of zero to 100, with zero being less suspicious and 100 being highly suspicious.

CureMetrix cmTriage is an investigational workflow optimization tool that enables a radiologist to customize their mammography worklist and clinical operations based on cases that may need immediate attention. This software is currently pending FDA approval and is being installed at multiple clinical sites in the U.S. and abroad this year.

http://curemetrix.com

**Densitas, Inc.**
The company received FDA clearance earlier this year for its machine learning breast density assessment software. Mohamed Abdolell, CEO, says a key distinction of DENSITASdensity is that, “Our solution uniquely operates on processed digital mammograms routinely stored on PACS and therefore integrates seamlessly into existing IT infrastructure and the radiology workflow. The mammograms are auto-routed from PACS to DENSITASdensity and the resulting density reports are sent back to PACS. IT administrators appreciate this fully PACS-centric integration as it permits a single point of integration versus multiple individual integrations to each modality. And radiologists appreciate being able to obtain breast density assessments on routinely archived prior digital mammograms as it can enhance their understanding of an individual’s risk of cancer.”

Abdolell says DENSITASdensity delivers accurate and reproducible density measurements from digital mammograms that inform how best to triage women with follow-up breast ultrasound and breast MRI. The company is currently collaborating with Leeds Teaching Hospitals NHS Trust in the UK and the provincial health system in Nova Scotia, Canada, to implement Densitas’ breast screening technologies.

“These agreements provide an opportunity to implement population-wide deployments of our full suite of technologies via a unified enterprise mammography solution across an entire health system,” Abdolell says. This will enable population-level research projects and tailored screening protocols based upon a woman’s breast density, overall cancer risk and mammography image quality.

He also believes that the ease of integration of DENSITASdensity via the “AI App Store” model through channel partnerships, such as with EnvoyAI, will be a significant enabler to adoption. A key factor in adoption of AI technologies, he says, is the value proposition that each solution provides. “AI is no different in breast imaging than any other area in radiology in that it needs to demonstrate value. If it does, and is properly validated, then these algorithms and applications will achieve the necessary regulatory clearances and will be used clinically to augment breast radiologists in their practice.”

https://densitas.health

**eVolutive Medica**
The Koios Decision Support (DS) platform is a patented cloud-based software based on proven machine learning algorithms that uses a database of medical imaging and pathology data to assist the radiologist in reading ultrasound images. According to the company’s website, sensitivity increases from 91-95% to 97%; benign biopsies are reduced between 25%-55% without reducing sensitivity; and the cancer identification rate is 100% with a 69% reduction in benign biopsies.

https://www.evolutivemedica.com/en-gb/home

**Hologic, Inc.**
Through a proprietary algorithm powered by machine learning, the FDA cleared Quantra 2.2 Breast Density Assessment Software analyzes mammography images for distribution and texture of breast tissue, delivering clinicians patient-specific breast density assessment. Quantra software categorizes breasts into four categories of density, in alignment with the ACR BI-RADS Atlas 5th Edition.

https://www.hologic.com

“‘There is promise that the enhanced pattern recognition in machine learning based tools will assist in the identification of cancers before they are evident to a radiologist reader.’”

Dr. Tanenbaum cautions, however, that accomplishing this requires a lot of heavy lifting. AI companies deliver or require high quality data that is characterized and annotated to generate high quality output with pathological proof for appropriate model training. He adds that ideally a data learning architecture could be applied to multiple varied applications across medical imaging, such as mammography, lung and colon screening.

Dr. Bahl agrees that development of AI in breast imaging, as well as other imaging specialties, will need a large number of cases for training the algorithms and that proprietary data may restrict access. However, she points out that through agreements such as the one between MIT and MGH, these barriers can be overcome. And the data that centers such as MGH generate—with upwards of 150 screening mammograms performed each day by Dr. Bahl’s estimate—is invaluable to the
development and validation of AI algorithms in breast imaging.

As director of the breast imaging fellowship program at MGH, Dr. Bahl believes it is important for current residents and fellows to understand AI terminology and use of this technology.

“Machine learning in breast imaging is in its infancy but I’m excited about its potential to improve clinical decision-making and decrease the morbidity and costs of overtreatment,” says Dr. Bahl.

“This is an exciting time for radiology,” Dr. Tanenbaum says. “AI will undoubtedly enhance our capabilities and importance in the imaging enterprise.”

**REFERENCES**


---

**iCad**

The PowerLook Breast Health Solutions built on deep learning delivers powerful software solutions for breast tomosynthesis, breast density and 2D mammography. Solutions include PowerLook Tomo Detection, PowerLook Density Assessment and PowerLook Mammo Detection. In early August 2018, the company announced FDA clearance for PowerLook Density Assessment Version 3.4, which delivers automated, rapid and reproducible assessments of breast density to help identify patients that may experience reduced sensitivity to digital mammography due to dense breast tissue.

http://www.icadmed.com

**Kheiron Medical Technologies**

With a focus on breast screening, the company is working on deep learning methods, data science and radiology insights to find malignancies in mammograms.

https://www.kheironmed.com

**QView Medical**

QVCAD is a next-generation CAD system for automated breast ultrasound systems (ABUS) based on deep learning algorithms that has received FDA clearance for use on the GE Invenia 3D ABUS. According to the company, when combined with ABUS, QVCAD with C-Thru technology has demonstrated a 33% improved reading time while preserving accuracy.

https://www.qviewmedical.com

**ScreenPoint Medical**

Algorithms in Transpara use state-of-the-art image analysis and revolutionary deep learning technology. Key features of the solution include decision support for suspicious areas, CAD, and exam selection for pre-screening. Transpara supports DICOM connectivity to PACS and FFDM modalities and uses DICOM CAD-SR for the display of regular CAD marks on a mammography reading station. Multi-vendor support is provided with CE approval for GE Healthcare, Siemens, Philips, and Hologic.

https://www.screenpoint-medical.com

**Therapixel**

The French start-up company won the DREAM Digital Mammography Challenge in 2017 with an algorithm that had a predictive accuracy of 80.3%, which is 5% more accurate than the runner up. Recently, the company announced Radvise, which integrates the company’s service of automatic image reading with a cloud-based platform for medical imaging sharing.

http://www.therapixel.com

**Volpara Solutions**

VolparaDensity software provides an objective volumetric measure of breast density from both digital mammography and tomosynthesis data. According to Chief Marketing Officer Julian Marshall, it reduces the variability in the reading of breast density. “If a radiologist is going to refer a patient to ultrasound or MRI for supplemental or high-risk screening, they shouldn’t use a subjective measure.”

VolparaEnterprise software is a suite of quantitative breast imaging tools for personalized measurements of density, patient-specific X-ray dose, breast compression, breast positioning, and other factors designed to provide critical insight for breast imaging quality and workflow. One goal of the software, says Marshall, is to provide feedback to the technologist so they can refine their technique to acquire better images. “The better the images, the more likely the radiologist can find disease. We are using our knowledge in mammography with AI to auto score these images and provide feedback.”

He cites a study by Katharina Holland, et al, that found if too much compression (pressure) is used during mammography, it may reduce sensitivity; too little compression (pressure) may decrease specificity.

This past spring, the company surpassed 1 million mammograms in its database, which Marshall says presents a tremendous opportunity for the company to continue analyzing the vast amount of data to further improve the breast screening process.

https://volparasolutions.com